• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性间皮瘤系统治疗的进展:未来展望。

Advances in systemic therapy for malignant mesothelioma: future perspectives.

机构信息

Department of Medical, Surgical, & Health Sciences, University of Trieste, Piazza Ospitale 1 34129 Trieste, Italy.

Department of Medical, Surgical, & Health Sciences, Teaching Hospital of Cattinara, University of Trieste, Via Fiume 447, 34129 Trieste, Italy.

出版信息

Future Oncol. 2017 Oct;13(23):2083-2101. doi: 10.2217/fon-2017-0224. Epub 2017 Oct 6.

DOI:10.2217/fon-2017-0224
PMID:28984470
Abstract

Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where asbestos has been used for industrial applications. Notwithstanding the progress made in the field, patients do not survive more than 12 months on average with standard treatment. With the advent of next generation sequencing, it is now possible to study the mutational landscape of each tumor with the aim of identifying the genetic aberrations driving tumorigenesis. This review encompasses the latest research in the field, with particular attention to new chemotherapy combinatorial regimens, molecular targets and immunotherapies, providing a comprehensive picture of the current and future treatment options for malignant mesothelioma patients.

摘要

恶性间皮瘤是一种罕见且侵袭性的癌症,影响间皮。这种主要的职业病在石棉被用于工业应用的国家中越来越常见。尽管在该领域取得了进展,但采用标准治疗的患者平均生存期不超过 12 个月。随着下一代测序的出现,现在可以研究每个肿瘤的突变景观,以确定导致肿瘤发生的遗传异常。本综述涵盖了该领域的最新研究,特别关注新的化疗联合方案、分子靶点和免疫疗法,为恶性间皮瘤患者提供了当前和未来治疗选择的全面图景。

相似文献

1
Advances in systemic therapy for malignant mesothelioma: future perspectives.恶性间皮瘤系统治疗的进展:未来展望。
Future Oncol. 2017 Oct;13(23):2083-2101. doi: 10.2217/fon-2017-0224. Epub 2017 Oct 6.
2
Optimal Therapy of Advanced Stage Mesothelioma.晚期间皮瘤的最佳治疗方法
Curr Treat Options Oncol. 2017 Aug;18(8):48. doi: 10.1007/s11864-017-0488-7.
3
Immunotherapy in relapsed mesothelioma.复发性间皮瘤的免疫治疗
Immunotherapy. 2018 Feb;10(2):77-80. doi: 10.2217/imt-2017-0144.
4
A catalogue of treatment and technologies for malignant pleural mesothelioma.恶性胸膜间皮瘤的治疗方法与技术目录
Expert Rev Anticancer Ther. 2016;16(4):455-63. doi: 10.1586/14737140.2016.1162100.
5
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.细胞减灭术 (CRS) 和腹腔热灌注化疗 (HIPEC) 后辅助树突状细胞免疫治疗 (DCBI) 治疗腹膜间皮瘤的 II 期单中心开放标签临床试验:MESOPEC 试验的原理和设计。
BMJ Open. 2019 May 14;9(5):e026779. doi: 10.1136/bmjopen-2018-026779.
6
A review of bevacizumab in the treatment of malignant pleural mesothelioma.贝伐珠单抗治疗恶性胸膜间皮瘤的研究进展。
Future Oncol. 2017 Dec;13(28):2537-2546. doi: 10.2217/fon-2017-0307. Epub 2017 Sep 20.
7
Is there a role for immunotherapy in malignant pleural mesothelioma?免疫疗法在恶性胸膜间皮瘤中的作用如何?
Med Oncol. 2018 May 29;35(7):98. doi: 10.1007/s12032-018-1156-x.
8
Advances in treatment of mesothelioma.间皮瘤治疗的进展。
Expert Opin Pharmacother. 2016 Jun;17(9):1197-205. doi: 10.1080/14656566.2016.1176145. Epub 2016 Apr 21.
9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.恶性胸膜间皮瘤的新辅助化疗和胸膜外全肺切除术联合或不联合半胸部放疗 (SAKK 17/04):一项随机、国际、多中心 2 期试验。
Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.
10
Malignant mesothelioma: development to therapy.恶性间皮瘤:从发病到治疗
J Cell Biochem. 2014 Jan;115(1):1-7. doi: 10.1002/jcb.24642.

引用本文的文献

1
Case Report: Primary malignant mesothelioma of the left atrium easily misdiagnosed as myxoma.病例报告:左心房原发性恶性间皮瘤易误诊为黏液瘤。
Front Cardiovasc Med. 2024 Jun 13;11:1398311. doi: 10.3389/fcvm.2024.1398311. eCollection 2024.
2
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.临床前评估 CDK4 磷酸化可预测胸膜间皮瘤对 CDK4/6 抑制的高敏感性。
Mol Oncol. 2024 Apr;18(4):866-894. doi: 10.1002/1878-0261.13351. Epub 2022 Dec 19.
3
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
肿瘤浸润淋巴细胞和 PD-L1 表达作为恶性胸膜间皮瘤患者预后的潜在预测指标。
Mol Biol Rep. 2019 Jun;46(3):2713-2720. doi: 10.1007/s11033-019-04715-9. Epub 2019 Mar 6.